Back to module
Evidence summary

Bone Loss, Fracture Risk and the Sarcopenia Overlap

Meridian · Women's Health After 50Generated: 4 August 2026

07Bone Loss, Fracture Risk and the Sarcopenia Overlap

The fastest bone loss of a woman's life happens in a four-year window most clinicians never screen.

Key takeaways

  • —Women lose roughly 2% of spinal BMD per year across the late transition and first postmenopausal years — around 10% in total.
  • —WHI showed MHT reduced hip and vertebral fractures in an unselected population — the only therapy to do so in women not selected for osteoporosis.
  • —FRAX does not capture falls risk, recent fracture recency, glucocorticoid dose or lumbar spine BMD — clinical judgement must override it.
  • —Stopping denosumab without follow-on antiresorptive therapy causes rapid rebound bone loss and multiple vertebral fractures.
  • —Progressive resistance plus impact training improves BMD modestly but improves falls risk and muscle function substantially.

Graded claims

A

MHT reduces hip and vertebral fracture risk in unselected postmenopausal women

Established — RCT / guideline-gradeWHI both arms — a rare positive primary-prevention fracture finding.

A

Bone loss accelerates in the late transition, before the final menstrual period

Established — RCT / guideline-gradeSWAN Bone substudy.

A

Stopping denosumab without follow-on therapy causes rebound vertebral fractures

Established — RCT / guideline-gradeFREEDOM extension analyses and multiple case series.

A

Progressive resistance training reduces falls and improves function in postmenopausal women

Established — RCT / guideline-gradeConsistent meta-analytic evidence.

E

Routine calcium plus vitamin D prevents fractures in replete community-dwelling adults

Popular, weak or conflicting supportUSPSTF and large meta-analyses show little to no benefit.

D

Whole body vibration platforms prevent fractures

Biologically plausible, unprovenSmall BMD signals, no fracture endpoint evidence.

Supporting references

  1. Bone mineral density changes during the menopause transition (SWAN) — Greendale et al., J Bone Miner Res 2012 https://pubmed.ncbi.nlm.nih.gov/22006037/
  2. Effects of Estrogen Plus Progestin on Risk of Fracture (WHI) — Cauley et al., JAMA 2003 https://pubmed.ncbi.nlm.nih.gov/14519709/
  3. Discontinuation of denosumab and associated vertebral fracture risk — Cummings et al., J Bone Miner Res 2018 https://pubmed.ncbi.nlm.nih.gov/29105841/
Educational summary for registered health professionals. Grades reflect strength of evidence at the time of writing and do not replace current national guidance, product licences or clinical judgement.